14Mar/14

Veloxis Pharmaceuticals A/S – Correction: US FDA Accepts Veloxis' New Drug … – Wall Street Journal

Veloxis Pharmaceuticals A/S – Correction: US FDA Accepts Veloxis’ New Drug
Wall Street Journal
Envarsus(R) is Veloxis’ once-daily tacrolimus based on the company’s proprietary MELTDOSE technology. Key points: — FDA has set a target review date under the Prescription Drug User Fee Act (PDUFA) of October 30, 2014 — The NDA was submitted to the 
Correction: U.S. FDA Accepts Veloxis’ New Drug Application for Envarsus® for GlobeNewswire (press release)

all 2 news articles »

14Mar/14

FDA Approves Merck's NOXAFIL® (posaconazole) Injection (18 mg/mL) for … – EIN News (press release)

FDA Approves Merck’s NOXAFIL® (posaconazole) Injection (18 mg/mL) for
EIN News (press release)
The administration of NOXAFIL with sirolimus, pimozide, quinidine, atorvastatin, lovastatin, simvastatin and ergot alkaloids must be avoided. When administered with NOXAFIL, some drugs such as cyclosporine and tacrolimus required dosage adjustments 

and more »

14Mar/14

FDA Approves Merck's NOXAFIL(R) (posaconazole) Injection (18 mg/mL) for … – Wall Street Journal

FDA Approves Merck’s NOXAFIL(R) (posaconazole) Injection (18 mg/mL) for
Wall Street Journal
The administration of NOXAFIL with sirolimus, pimozide, quinidine, atorvastatin, lovastatin, simvastatin and ergot alkaloids must be avoided. When administered with NOXAFIL, some drugs such as cyclosporine and tacrolimus required dosage adjustments 

and more »

14Mar/14

FDA Approves Merck's NOXAFIL® (posaconazole) Injection (18 mg/mL) for … – MarketWatch


Drug Discovery & Development

FDA Approves Merck’s NOXAFIL® (posaconazole) Injection (18 mg/mL) for
MarketWatch
The administration of NOXAFIL with sirolimus, pimozide, quinidine,atorvastatin, lovastatin, simvastatin and ergot alkaloids must be avoided. When administered with NOXAFIL, some drugs such as cyclosporine and tacrolimus required dosage adjustments and
FDA Approves Merck’s NOXAFIL(R) (posaconazole) Injection (18 mg/mL) for Wall Street Journal

all 10 news articles »

14Mar/14

FDA Approves Merck's NOXAFIL ® (posaconazole) Injection (18 mg/mL) for … – Business Wire (press release)

FDA Approves Merck’s NOXAFIL ® (posaconazole) Injection (18 mg/mL) for
Business Wire (press release)
The administration of NOXAFIL with sirolimus, pimozide, quinidine, atorvastatin, lovastatin, simvastatin and ergot alkaloids must be avoided. When administered with NOXAFIL, some drugs such as cyclosporine and tacrolimus required dosage adjustments